Advaxis (ADXS) Enters $30M Definitive Securities Purchase Agreement with Healthcare Specialist Investors
Advaxis, Inc. (NASDAQ: ADXS), a Princeton-based biotechnology company focused on the development of cancer immunotherapies, recently announced that it has entered into direct placement financing with healthcare specialist investors worth around $30 million. Advaxis will be selling 2.2 million shares of its common stock at $13.50 per share. Advaxis is offering these shares pursuant to a shelf registration statement on Form S-3 (File No. 333-203497) that, on April 27, 2015, the Securities and Exchange Commission (SEC) deemed effective. Jefferies LLC and Barclays Capital, Inc. are the companies acting as the lead intermediaries, with Cantor Fitzgerald & Co. and Guggenheim Securities,…